**Supplementary Figure 2.** We divided with the subjects into three groups; IT-group (n=91), AVT-group (n=928) (both groups stringently defined by a low FIB-4 index), and patients undergoing AVT with high FIB-4 (n=1,052). The cumulative probabilities of HCC development were not significantly different between these groups (overall P<0.001). HCC, hepatocellular carcinoma; IT, immune-tolerant; AVT, antiviral therapy; FIB-4, fibrosis-4.